Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Jennifer Ferguson 1 , Michael Smith 1 , Isabel Zudaire 2 , Claudia Wellbrock 1 , Imanol Arozarena 1, 2 1 Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, Manchester, UK 2 Navarrabiomed-Fundación Miguel Servet-Idisna, Calle Irunlarrea, 3 Complejo Hospitalario de Navarra, 31008, Pamplona, Spain Correspondence to: Imanol Arozarena, email: iarozarm@navarra.es Claudia Wellbrock, email: Claudia.Wellbrock@manchester.ac.uk Keywords: melanoma, glucose, MITF, ATF4, ROS Received: September 18, 2016 Accepted: March 13, 2017 Published: March 23, 2017 ABSTRACT It is well know that cancer cells have adopted an altered metabolism and that glucose is a major source of energy for these cells. In melanoma, enhanced glucose usage is favoured through the hyper-activated MAPK pathway, which suppresses OXPHOS and stimulates glycolysis. However, it has not been addressed how glucose availability impacts on melanoma specific signaling pathways that drive melanoma cell proliferation. Here we show that melanoma cells are dependent on high glucose levels for efficient growth. Thereby, glucose metabolism controls the expression of the melanoma fate transcription factor MITF, a master regulator of melanoma cell survival and proliferation, invasion and therapy resistance. Restriction of glucose availability to physiological concentrations induces the production of reactive oxygen species (ROS). Increased ROS levels lead to the up-regulation of AFT4, which in turn suppresses MITF expression by competing with CREB, an otherwise potent inducer of the MITF promoter. Our data give new insight into the complex regulation of MITF, a key regulator of melanoma biology, and support previous findings that link metabolic disorders such as hyperglycemia and diabetes with increased melanoma risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398 · cited 1×
“Increased ROS levels have been shown to effectively suppress RHO-ROCK mediated rounded-amoeboid invasion [47], but on the other hand an aged microenvironment induces ROS in melanoma cells, which creates slow-growing invasive tumours with increased potency to metastasise to the lung [48].”
BackgroundRetractedGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000 · cited 1×
“com/oncotarget described that oxidative stress can induce the expression of HIF1alpha, which can repress MITF expression under low oxygen conditions [28, 29], but under our experimental conditions, glucose restriction did not induce HIF1alpha expression (Supplementary Figure 4).”
BackgroundOncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · cited 1×
“In melanoma, enhanced glucose usage is favoured through the hyper-activated MAPK pathway, which suppresses OXPHOS and stimulates glycolysis [4, 5] Research Paper”
BackgroundLow MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639 · cited 1×
“Furthermore cells cultured at 5 mM glucose increase the levels of the tyrosine kinase receptor AXL, a marker for melanoma cells with a more invasive phenotype (Supplementary Figure 5B) [40], and indeed glucose restriction significantly increases melanoma cell invasiveness through collagen I 3D-matrices (Supplementary…”
BackgroundMitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Dunbar, E. M., Coats, B. S., Shroads, A. L., Langaee, T., Lew, A., Forder, J. R., Shuster, J. J., Wagner, D. A., & Stacpoole, P. W. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0047-4 · Cited by 241
Cotter, M. A., Thomas, J., Cassidy, P., Robinette, K., Jenkins, N., Florell, S. R., Leachman, S., Samlowski, W. E., & Grossman, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1187 · Cited by 92 · cited 1×
“In melanoma ROS can contribute to the accumulation of mutations via UV-induced mutagenicity, and there is evidence suggesting ROS production is required to promote melanoma initiation and that anti-oxidants would have a protective effect against melanoma onset [43, 44].”
BackgroundPark, S. G., Lee, J. H., Lee, W. A., & Han, K. M. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.07.003 · Cited by 51
Cited by
Goding, C. R., & Arnheiter, H. (2019) · Genes & Development · doi:10.1101/gad.324657.119 · Cited by 430
“CREB enables MITF-M expression to be responsive to elevated cAMP levels downstream from the melanocortin 1 receptor that is implicated in control of hair and skin pigmentation at least in part via its ability to regulate MITF expression.”
InfluentialPhenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Self-citationMelanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
Kim, M., Gwak, J., Hwang, S., Yang, S., & Jeong, S. M. (2019) · Oncogene · doi:10.1038/s41388-019-0751-4 · Cited by 74
Varum, S., Baggiolini, A., Zurkirchen, L., Atak, Z. K., Cantù, C., Marzorati, E., Bossart, R., Wouters, J., Häusel, J., Tuncer, E., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.011 · Cited by 65
Metadata
- Authors
- Ferguson, J., Smith, M., Zudaire, I., Wellbrock, C., & Arozarena, I.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-03-23
- Volume
- 8
- Issue
- 20
- Pages
- 32946-32959
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2599300818
- Cited by
- 76
- References
- 9
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.